AU2020394867A1 - Polyheterocyclic compounds as METTL3 inhibitors - Google Patents

Polyheterocyclic compounds as METTL3 inhibitors Download PDF

Info

Publication number
AU2020394867A1
AU2020394867A1 AU2020394867A AU2020394867A AU2020394867A1 AU 2020394867 A1 AU2020394867 A1 AU 2020394867A1 AU 2020394867 A AU2020394867 A AU 2020394867A AU 2020394867 A AU2020394867 A AU 2020394867A AU 2020394867 A1 AU2020394867 A1 AU 2020394867A1
Authority
AU
Australia
Prior art keywords
methyl
indol
alkyl
oxo
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020394867A
Other languages
English (en)
Inventor
Wesley Peter Blackaby
Frederick Arthur Brookfield
Christian Bubert
David James Hardick
Mark Peter Ridgill
Jon SHEPHERD
Elizabeth Jane THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Storm Therapeutics Ltd
Original Assignee
Storm Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917603.1A external-priority patent/GB201917603D0/en
Priority claimed from GBGB2015692.3A external-priority patent/GB202015692D0/en
Priority claimed from GBGB2015820.0A external-priority patent/GB202015820D0/en
Application filed by Storm Therapeutics Ltd filed Critical Storm Therapeutics Ltd
Publication of AU2020394867A1 publication Critical patent/AU2020394867A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020394867A 2019-12-02 2020-12-01 Polyheterocyclic compounds as METTL3 inhibitors Pending AU2020394867A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1917603.1A GB201917603D0 (en) 2019-12-02 2019-12-02 Inhibitory compounds
GB1917603.1 2019-12-02
GB2015692.3 2020-10-02
GBGB2015692.3A GB202015692D0 (en) 2020-10-02 2020-10-02 Inhibitory compounds
GB2015820.0 2020-10-06
GBGB2015820.0A GB202015820D0 (en) 2020-10-06 2020-10-06 Inhibitory compounds
PCT/GB2020/053081 WO2021111124A1 (en) 2019-12-02 2020-12-01 Polyheterocyclic compounds as mettl3 inhibitors

Publications (1)

Publication Number Publication Date
AU2020394867A1 true AU2020394867A1 (en) 2022-05-26

Family

ID=73854829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394867A Pending AU2020394867A1 (en) 2019-12-02 2020-12-01 Polyheterocyclic compounds as METTL3 inhibitors

Country Status (11)

Country Link
US (3) US12195458B2 (enExample)
EP (1) EP4069694A1 (enExample)
JP (2) JP7765088B2 (enExample)
KR (1) KR20220113431A (enExample)
CN (1) CN115151540A (enExample)
AU (1) AU2020394867A1 (enExample)
BR (1) BR112022010561A2 (enExample)
CA (1) CA3162166A1 (enExample)
IL (1) IL293340A (enExample)
MX (1) MX2022006700A (enExample)
WO (1) WO2021111124A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
WO2022074379A1 (en) * 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
GB202107905D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Processes for the preparation of inhibitory compounds
GB202107907D0 (en) * 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
CN115894447B (zh) * 2021-09-22 2024-10-01 成都先导药物开发股份有限公司 Mettl3抑制剂及其用途
CN116514805A (zh) * 2021-12-10 2023-08-01 成都先导药物开发股份有限公司 Mettl3抑制剂化合物
US20250059207A1 (en) * 2021-12-29 2025-02-20 858 Therapeutics, Inc. 6,6-fused heterocyclic compounds as mettl3 inhibitors
CN118660890A (zh) 2022-02-11 2024-09-17 西藏海思科制药有限公司 一种mettl3抑制剂及组合物及其在医药上的应用
WO2023235756A1 (en) * 2022-05-31 2023-12-07 The Trustees Of The University Of Pennsylvania Compounds for the treatment of hiv
CN117720533A (zh) * 2022-09-16 2024-03-19 北京华益健康药物研究中心 Mettl3抑制剂化合物及其药物组合物和应用
GB202218672D0 (en) 2022-12-12 2023-01-25 Storm Therapeutics Ltd Inhibitory compounds
CN120731203A (zh) 2023-01-20 2025-09-30 艾匹克治疗公司 作为mettl3抑制剂的哌啶衍生物
AU2024244637A1 (en) 2023-03-30 2025-10-16 Aqemia Novel mettl3 inhibitors and use thereof in therapy
CN119899188A (zh) * 2023-10-26 2025-04-29 杭州邦顺制药有限公司 Mettl3抑制剂
GB202316595D0 (en) 2023-10-30 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
GB202316683D0 (en) 2023-10-31 2023-12-13 Storm Therapeutics Ltd Inhibitory compounds
WO2025242921A1 (en) 2024-05-23 2025-11-27 Storm Therapeutics Limited Processes for the preparation of inhibitory compounds
WO2026067558A1 (zh) * 2024-09-25 2026-04-02 中国科学院上海药物研究所 稠合双环类化合物及其制备方法、组合物和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
FR2734814B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US5928323A (en) 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1250446A (zh) 1997-03-21 2000-04-12 诺瓦提斯公司 作为除草剂的吡唑衍生物
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US20040077557A1 (en) 2000-12-21 2004-04-22 Sulejman Ali Macrolide antibiotics
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
US7169795B2 (en) 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
BRPI0611948A2 (pt) 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
ES2340531T3 (es) 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CN101379060B (zh) * 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
US8163760B2 (en) 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas
WO2008016666A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
ES2420479T3 (es) * 2006-08-31 2013-08-23 Sk Chemicals, Co., Ltd. Procedimiento para la producción de microesferas cargadas con fármacos y microesferas cargadas con fármacos producidas mediante el mismo
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
JP5208962B2 (ja) 2006-12-22 2013-06-12 アベキサ・リミテッド 二環式ピリミジノンおよびその使用
CN101636398A (zh) * 2007-02-05 2010-01-27 泽农医药公司 用于治疗钠通道介导的疾病或疾病状态的吡啶并嘧啶酮化合物
CA2677813A1 (en) 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
JP2011511800A (ja) 2008-02-07 2011-04-14 アボット・ラボラトリーズ 正のアロステリックな修飾物質としてのアミド誘導体およびこれらの使用方法
TW201004939A (en) 2008-04-17 2010-02-01 Glaxo Group Ltd Novel compounds
EP2297140A4 (en) 2008-06-06 2012-05-02 Abbott Lab NOVEL 1,2,4-OXADIAZOLE COMPOUNDS AND METHODS OF USE
JP5592360B2 (ja) 2008-07-02 2014-09-17 アベキサ・リミテッド イミダゾピリミジノンおよびその使用
CA2729649A1 (en) 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
PL2212324T3 (pl) 2008-07-02 2014-11-28 Avexa Ltd Związki posiadające właściwości przeciwwirusowe
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
WO2010074101A1 (ja) 2008-12-25 2010-07-01 住友化学株式会社 アミノピリジン化合物及びその用途
WO2010114898A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
CN102336751A (zh) 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
TW201245185A (en) 2011-04-01 2012-11-16 Lundbeck & Co As H New positive allosteric modulators of nicotinic acetylcholine receptor
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
WO2014063199A1 (en) 2012-10-26 2014-05-01 Akaal Pharma Pty Ltd Organic compounds
JP6520705B2 (ja) 2013-03-19 2019-05-29 凸版印刷株式会社 Ｅｇｆｒ阻害剤感受性予測方法
EP3082820B1 (en) * 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015192760A1 (zh) 2014-06-17 2015-12-23 南京明德新药研发股份有限公司 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物
WO2015192761A1 (zh) 2014-06-17 2015-12-23 辰欣药业股份有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
US10702521B2 (en) 2014-08-22 2020-07-07 Glaxosmithkline Intellectual Property Development Limited Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
US20180305391A1 (en) * 2015-10-22 2018-10-25 Memorial Sloan-Kettering Cancer Center Cofactor analogs as methyltransferase inhibitors for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10730903B2 (en) * 2016-09-19 2020-08-04 Memorial Sloan-Kettering Cancer Center Adenosine analogs as methyltransferase inhibitors for treating cancer
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
JP7142675B2 (ja) 2017-03-26 2022-09-27 武田薬品工業株式会社 Ｇｐｒ６のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
CN107349217B (zh) * 2017-07-21 2020-06-09 深圳大学 一种基于mettl3的小干扰rna及其药物和应用
EP3589745A1 (en) * 2018-04-11 2020-01-08 Chemestmed Ltd. A method of modulating the rna methylation
CN112585119A (zh) 2018-08-14 2021-03-30 Epizyme股份有限公司 经取代的吲哚及其使用方法
MX2021006347A (es) 2018-11-30 2021-10-13 Epizyme Inc Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物

Also Published As

Publication number Publication date
US20230002378A1 (en) 2023-01-05
CN115151540A (zh) 2022-10-04
WO2021111124A1 (en) 2021-06-10
BR112022010561A2 (pt) 2022-11-16
JP2026027269A (ja) 2026-02-18
JP7765088B2 (ja) 2025-11-06
EP4069694A1 (en) 2022-10-12
US20250122195A1 (en) 2025-04-17
US12195458B2 (en) 2025-01-14
JP2023506147A (ja) 2023-02-15
MX2022006700A (es) 2022-09-02
CA3162166A1 (en) 2021-06-10
KR20220113431A (ko) 2022-08-12
US20230116403A1 (en) 2023-04-13
IL293340A (en) 2022-07-01
US11725010B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
US11725010B2 (en) Polyheterocyclic compounds as METTL3 inhibitors
US20250388577A1 (en) Mettl3 inhibitory compounds
AU2020220079B2 (en) Heterocyclic compounds as RET kinase inhibitors
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
JP6297570B2 (ja) 薬理活性化合物
WO2022074379A1 (en) Mettl3 inhibitory compounds
CN106459035B (zh) N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途
WO2022074391A1 (en) Compounds inhibitors of mettl3
WO2024126987A1 (en) Inhibitory compounds
WO2025104443A1 (en) Inhibitory compounds
RU2858287C2 (ru) Полигетероциклические соединения в качестве ингибиторов mettl3
CA3020778C (en) Heterocyclic compounds as ret kinase inhibitors